Iovance Biotherapeutics (IOVA) investor relations material

Executive summary

• Achieved 45% year-over-year revenue growth in Q1 2026 to $71.4M, driven by strong Amtagvi and Proleukin sales and operational improvements.

• Net loss narrowed by 32% to $79M, reflecting higher sales and reduced operating expenses.

• Amtagvi adoption and referral trends reached all-time highs, with commercial launch progressing in the U.S. and expansion plans for global markets.

• Manufacturing centralized at iCTC, improving cost efficiency and enabling uninterrupted in-house Amtagvi production.

• Strategic restructuring in August 2025 reduced workforce by 19% to optimize costs.

Financial highlights

• Q1 2026 revenue was $71.4M, up from $49.3M in Q1 2025; Amtagvi revenue was $60.2M, Proleukin revenue $11.2M.

• Gross margin from cost of sales was 41%, impacted by one-time facility upgrade costs.

• R&D expenses declined for the third consecutive quarter, down 18% year-over-year and 12% sequentially.

• SG&A expense was $38.9M, down 11% year-over-year.

• Cash, equivalents, and investments totaled $319.4M as of March 31, 2026.

Outlook and guidance

• Q2 2026 total revenue guidance: $86M–$88M; Amtagvi revenue expected at $79M–$81M.

• Full-year 2026 revenue guidance for Amtagvi and Proleukin: $350M–$370M.

• Projecting $1B peak sales trajectory for Amtagvi and Proleukin in the U.S.

• Gross margins expected to trend higher for the remainder of 2026 as operational efficiencies increase.

• Cash reserves and expense reductions expected to support operations into 2028.